¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tumor associated rejection antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® rejection ÇÑ±Û °ÅºÎ
¼³¸í   
  ¾î¶² °³Ã¼ÀÇ Á¶Á÷À» ´Ù¸¥ °³Ã¼¿¡ À̽ÄÇßÀ» ¶§ ±×°ÍÀ» ¹èÁ¦Çϴ »ýü¹ÝÀÀ. °³Ã¼°£¿¡ À̽ļö¼úÀ» Çϸé Ã³À½ 7~10ÀÏ Á¤µµ´Â Ç÷¾×°ø±Þµµ È¸º¹µÇ°í º°´Ù¸¥ ÀÌ»óÀ» ¹ß°ßÇÏÁö ¸øÇÏÁö¸¸, ±× ÈÄ¿¡ ±«»ç°¡ »ý±ä´Ù. ±× ¶§¹®¿¡ Àå±âÀ̽ĠÈÄ¿¡ °¢Á¾ Áõ»óÀÌ ¹ß»ýÇÏ¿© À̽ļö¼úÀÌ ½ÇÆÐ·Î µ¹¾Æ°¡±â ½±´Ù. »ç¶÷ÀǠü³»¿¡ ÀÌÁ¾ÀÇ Á¶Á÷ÀÌ µé¾î°¡¸é ±×¿¡ ´ëÇØ Ç×ü°¡ ¸¸µé¾îÁø´Ù. À̴ Ç÷¾× ¼ÓÀÇ ¸²ÇÁ±¸°¡ ±× ÀÌÁ¾Á¶Á÷¿¡ Á¢ÃËÇÏ¿© È°¼ºÈ­µÈ »óÅ¿¡¼­ ¸²ÇÁÀý·Î µÇµ¹¾Æ¿Í¼­ °Å±â¼­ Ç×ü¸¦ ¸¸µå´Â °ÍÀ¸·Î »ý°¢µÇ°í ÀÖ´Ù. ÀÌ Ç×ü´Â ¼¼Æ÷¼ºÇ×ü¿Í Ã¼¾×¼ºÇ×ü·Î ³ª´©¾îÁö¸ç ÀÌ ¾çÀÚÀÇ °øµ¿ÀÛ¿ë¿¡ ÀÇÇØ °ÅºÎ¹ÝÀÀÀÌ »ý±â´Â °ÍÀ¸·Î º¸ÀδÙ. À̴ °³Ã¼¹æÀ§¹ÝÀÀÀ̶ó°íµµ ÇÒ ¼ö ÀÖÁö¸¸ À̽ÄÁ¶Á÷ÀÇ Ç÷°üÀº ±×°ÍµéÀÇ ÀÛ¿ëÀ¸·Î ³»ÇǼ¼Æ÷°¡ »óÇÏ¿© Ç÷ÀüÀ» Çü¼ºÇϹǷΠÇ÷ÇàÀÌ µÎÀýµÈ´Ù. ±× ¶§¹®¿¡ ±«»ç°¡ »ý±â°í ±«»çÁ¶Á÷Àº Ã¼¿Ü·Î ¹èÃâµÈ´Ù. °ÅºÎ¹ÝÀÀÀº À̽ÄÁ÷ÈÄ¿¡ »ý±â´Â °Í, ¼öÁÖ¿¡¼­ ¼ö°³¿ù ÈÄ¿¡ ºñ±³Àû ±Þ¼ºÀ¸·Î »ý±â´Â °Í, ¼ö³â ÈÄ¿¡ ¼­¼­È÷ »ý±â´Â °ÍÀÌ ÀÖ´Ù. Àå±â À̽Ľÿ¡´Â ÀÌ ¹ÝÀÀÀ» ¾ïÁ¦Çϱâ À§ÇØ ¸é¿ª¾ïÁ¦Á¦³ª ºÎ½Å°ÑÁúÈ£¸£¸óÀ» Åõ¿©ÇÑ´Ù. 
¿µ¹® carcinoembryonic antigen ÇÑ±Û ¾Ï¹è¾ÆÇ׿ø
¼³¸í   
  ¿ø·¡ Å¾ÆÀÇ ÀåÁ¶Á÷¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇϴ ¹°Áú·Î Å¾Ʊâ ÀÌÈÄ¿¡´Â Á¸ÀçÇÏÁö ¾Ê´Â ¹°ÁúÀÌ´Ù. ±×·¯³ª À§, °£, ÇãÆÄ µîÀÇ ¾ÏÀÌ Àִ °æ¿ì¿¡ ¼ºÀο¡¼­µµ Á¸ÀçÇÑ´Ù. À̸¦ ÀÌ¿ëÇØ¼­ ¾ÏÀÇ Ä¡·áÈ¿°ú ÆÇÁ¤À̳ª Àç¹ß¿©ºÎÀÇ Á¶»ç¿¡ ÀÌ¿ëÇÑ´Ù.
¿µ¹® antigen ÇÑ±Û Ç׿ø
¼³¸í   
  Æ¯ÀÌÇÑ ¸é¿ª¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¾î¶°ÇÑ ¹°Áú. ¿©±â¿¡¼­ ¸»Çϴ ƯÀÌÇÑ ¸é¿ª¹ÝÀÀÀ̶õ ºñƯÀÌÀûÀΠ¸é¿ª¹ÝÀÀ°ú´Â ¹Ý´ëµÇ´Â Àǹ̷Π±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ Ç×ü³ª ±× ¹°Áú¿¡ ´ëÇØ¼­ Æ¯ÀÌÇϰԠ¹ÝÀÀÇÒ ¼ö Àִ ¼¼Æ÷¸¦ ¸¸µå´Â °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® solid tumor ÇÑ±Û °íÇüÁ¾¾ç
¼³¸í   
  ¼¼Æ÷·Î ²Ë Âù Á¾¾çÀ» ¸»ÇÔ. ¹éÇ÷º´ µîÀÇ Ç÷¾×¾Ï°ú °°ÀÌ ÇüŸ¦ ÃëÇÏÁö ¾Ê°í ¾×üÀΠ»óÅÂÀÇ ¾Ï°ú ´ëÁ¶µÇ´Â ¿ë¾î·Î¼­ ´Ü´ÜÇÑ µ¢¾î¸®·Î ±¸¼ºµÈ ¾Ç¼ºÁ¾¾çÀÌ´Ù. ´ëºÎºÐÀÇ Á¾¾çÀÌ ÀÌ¿¡ ÇØ´çÇÑ´Ù. Æ¯È÷ Ç¥ÇÇÁ¶Á÷¿¡¼­ ±â¿øÇÑ Á¾¾çÀ» ¸»ÇÑ´Ù.
¿µ¹® ulcerating tumor ÇÑ±Û ±Ë¾ç¼º Á¾¾ç
¼³¸í   
  Á¾¾çÀǠǥ¸é¿¡ ±Ë¾çÀÌ ¹ß»ýÇϴ °Í. ´ë°³, ¸Å¿ì »¡¸® ÀÚ¶ó´Â Á¾¾ç¿¡¼­ Ç÷·ù °ø±ÞÀÌ Á¾¾ç¼¼Æ÷ÀÇ ÀÚ¶ó´Â ¼Óµµ¸¦ °¨´çÇÏÁö ¸øÇØ Á¾¾çÁ߽ɺΠÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁ® ±Ë¾çÀ» Çü¼ºÇϴ °æ¿ì°¡ ¸¹´Ù. À°¾ÈÀ¸·Î º¸¸é »¡°²°í, ¿­À̳ª¸ç, ÁöÀúºÐÇØ º¸ÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • allograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • cardiac rejection
    ½ÉÀåÀ̽İźιÝÀÀ
  • first-set rejection
    ÀÏÂ÷°ÅºÎ¹ÝÀÀ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ¹ÝÀÀ
  • homograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • rejection
    1. °ÅºÎ, °ÅºÎ¹ÝÀÀ 2. °ÅÀý 3. Æó±â
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • specimen rejection
    °Ëü°ÅÀý
  • antibiotic-associated
    Ç×»ýÁ¦°ü·Ã-
  • associated defect
    ¿¬°üÀå¾Ö
  • associated movement
    ¿¬Çտ
  • associated reaction
    ¿¬ÇÕ¹ÝÀÀ
  • adeno-associated satellite virus
    ¾Æµ¥³ë°ü·ÃÀ§¼º¹ÙÀÌ·¯½º
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã¹ÙÀÌ·¯½º
  • croup-associated virus
    Å©·çÇÁ°ü·Ã¹ÙÀÌ·¯½º
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor antigen
    Á¾¾çÇ׿ø
  • rejection
    °ÅºÎ
  • allograft rejection
    µ¿Á¾À̽İźÎ
  • rejection reaction
    °ÅºÎ¹ÝÀÀ
  • sex cord-stromal tumor tumor
    ¼º²ö°£ÁúÁ¾¾ç, ³­¼Ò¹öÆÀÁúÁ¾¾ç
  • antigen
    Ç׿ø
  • antigen analysis
    Ç׿øºÐ¼®
  • carcinoembryonic antigen
    ¾ÏÁ¾¹è¾ÆÇ׿ø
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • recombinant antigen
    ÀçÁ¶ÇÕÇ׿ø
  • sequestered antigen
    °Ý¸®Ç׿ø
  • somatic antigen
    ü¼¼Æ÷Ç׿ø, ±ÕüÇ׿ø
  • surface antigen
    Ç¥¸éÇ׿ø
  • antigen excess
    Ç׿ø°úÀ×
  • antigen presentation
    Ç׿øÀü´Þ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor antigen
    Á¾¾çÇ׿ø
  • antibiotic-associated
    Ç×»ýÁ¦°ü·Ã-
  • adeno-associated virus
    ¾Æµ¥³ë¹ÙÀÌ·¯½ºÀÇÁ¸¹ÙÀÌ·¯½º
  • associated defect
    ¿¬ÇÕ°áÇÔ, ¿¬ÇÕ°á¼Õ, ¼ö¹ÝÀå¾Ö
  • associated movement
    ¿¬Çտ
  • associated reaction
    ¿¬ÇÕ¹ÝÀÀ
  • cell-associated antibody
    ¼¼Æ÷ºÎÂøÇ×ü
  • cell-associated virus
    ¼¼Æ÷ºÎÂø¹ÙÀÌ·¯½º
  • croup-associated virus
    Å©·ì°ü·Ã¹ÙÀÌ·¯½º
  • gut-associated lymphatic tissue
    âÀÚ¿¬°ü¸²ÇÁÁ¶Á÷
  • allograft rejection
    µ¿Á¾À̽İźÎ
  • cardiac rejection
    ½ÉÀåÀ̽İźιÝÀÀ
  • first-set rejection
    ÀÏÂ÷°ÅºÎ
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • I region-associated antigen
    Ir¿¬°üÇ׿ø
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã(¡­Î¼æá) ¹ÙÀÌ·¯½º.
  • adeno-associated virus
    ¾Æµ¥³ë°ü·Ã(¡­Î¼æá) ¹ÙÀÌ·¯½º.
  • adeno-associated virus
    ¾Æµ¥³ë(¹ÙÀÌ·¯½º) ÀÇÁ¸ ¹ÙÀÌ·¯½º
  • age-associated memory impairment
    ¿¬·É°ü·Ã ±â¾ï·Â Àå¾Ö(¼Õ»ó)
  • antibiotic-associated colitis/diarrhea
    Ç×»ýÁ¦À¯¹ß´ëÀå¿°, Ç×»ýÁ¦À¯¹ß¼³»ç
  • gut-associated lymphatic tissue (GALT)
    Àå-¿¬°ü ¸²ÇÁÁ¶Á÷
  • antigen, tumor-specific
    Á¾¾çƯÀÌÇ׿ø
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ).
  • graft rejection, white
    ¹é»öÈ­ ÀÌ½ÄÆí°ÅºÎ (Ãʱ޼º)
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­°ÅºÎ¹ÝÀÀ).
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­ËÞÜúÚãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor associated rejection antigen
    Á¾¾ç°ü·Ã°ÅºÎÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antigen,fetal tumor-associated
    žÆÁ¾¾ç °ü·Ã¼º(÷Ãä®ðþåË Î¼Ö¤àõ)
  • fetal tumor-associated antigen
    ÅÂ¾Æ Á¾¾ç °ü·Ã Ç׿ø
  • tumor associated antigen
    Á¾¾ç°ü·ÃÇ׿ø
  • tumor-associated antigen
    Á¾¾ç°ü·ÃÇ׿ø
  • antigen, I region-associated
    Ir¿¬°üÇ׿ø
  • cell associated antigen
    ¼¼Æ÷¿¬°üÇ׿ø
  • capsular antigen =K. antigen
    Çù¸·Ç׿ø(¡­ù÷ê«).
  • allograft rejection
    µ¿Á¾À̽İźιÝÀÀ
  • allograft rejection
    µ¿Á¾À̽Ä[Æí]°ÅºÎ[¹ÝÀÀ]
  • allograft rejection =homograft r.
    µ¿Á¾À̽Ä(Æí) °ÅºÎ(¹ÝÀÀ).
  • first set rejection
    1Â÷°ÅºÎ(¹ÝÀÀ).
  • first set rejection
    ÀÏÂ÷°ÅºÎ(¹ÝÀÀ).
  • graft rejection
    ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ).
  • graft rejection, white
    ¹é»öÈ­ ÀÌ½ÄÆí°ÅºÎ (Ãʱ޼º)
  • homograft rejection
    µ¿Á¾ÀÌ½ÄÆí°ÅºÎ(¹ÝÀÀ)(¡­ËÞÜúÚãëë).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Deficiency (Monstrous tumor)
    °áÇÌ (±«¹°Á¾)
    [¿¾ ¿ë¾î] °áÇÌ
  • Monstrous tumor
    ±«¹°Á¾
    [¿¾ ¿ë¾î] ±«¹°Á¾
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • circumsporozoite antigen
    Æ÷ÀÚ¼ÒüÇ׿ø
  • egg antigen
    Ãæ¶õÇ׿ø
  • excretory-secretory antigen
    ºÐºñ¹è¼³Ç׿ø
  • metabolic antigen
    ´ë»çÇ׿ø
  • somatic antigen
    üÇ׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • immunological rejection
    ¸é¿ª °ÅºÎ(Øóæ¹ËÞÜú)
  • trnsplant rejection
    À̽ÄÁ¶Á÷ °ÅºÎ(ì¹ãÕðÚòÄËÞÜú)
  • adenovirus-associated virus
    ¾Æµ¥³ë¹ÙÀÌ·¯½º¿¬°è(ææÍ¨) ¹ÙÀÌ·¯½º
  • I region-associated protein
    I ºÎÀ§¿¬°ü(Ý»êÈ֤μ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • microtubule-associated proteins
    ¹Ì¼Ò°ü ¿¬°ü´Ü¹éÁú(Ú°á³Î·æáμӱÛÜòõ)
  • ectopic tumor
    ÀÌ¼Ò Á¾¾ç(ì¶á¶ðþåË)
  • Ehrlich ascites tumor
    ¿¡¸¦¸®È÷ º¹¼öÁ¾(ÜÙâ©ðþ)
  • primary tumor
    ¿ø¹ß¼º Á¾¾ç(ê«Û¡àõðþåË)
  • tumor angiogenesis facotr
    Á¾¾ç Ç÷°üÇü¼ºÀÎÀÚ(ðþåËúìηû¡à÷ì×í­)
  • tumor initiator
    Á¾¾ç °³½ÃÀÚ(ðþåËËÒã·í­)
  • tumor necrosis factor
    Á¾¾ç ±«»çÀÎÀÚ(ðþåËÎÕÞÝì×í­)
  • tumor progression
    Á¾¾çÁøÇà(ðþåËòäú¼)
  • tumor promoter
    Á¾¾çÃËÁøÀÚ(ðþåËõµòäí­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • MALT(mucosa associated lymphoid tissue)
    Á¡¸·°ü·Ã¸²ÇÁÁ¶Á÷
  • rejection
    °ÅÀý, °ÅºÎ, ±â°¢
  • transplant rejection
    À̽İźÎ
  • antigen
    Ç׿ø
  • antigen antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • HLA antigen
    HLAÇ׿ø
  • HLA[=human leukocyte antigen]
    HLAÇ׿ø, Àΰ£¹éÇ÷±¸Ç׿ø
  • homologous antigen
    »óµ¿Ç׿ø
  • benign tumor
    ¾ç¼ºÁ¾¾ç
  • brown tumor
    °¥»öÁ¾¾ç
  • carotid body tumor
    °æµ¿¸Æ¼ÒüÁ¾¾ç
  • giant cell tumor
    °Å¼¼Æ÷Á¾¾ç
  • glomus jugulare tumor
    °æÁ¤¸Æ±¸Á¾¾ç
  • glomus tumor
    »ç±¸Á¾¾ç, ±Û·Î¹«½ºÁ¾¾ç
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TARA total articular replacement arthroplasty; tumor-associated rejection antigen
TSA technical surgical assistance; toluene sulfonic acid; total shoulder arthroplasty; total solute abso...
TSTA toxoplasmin skin test antigen; tumor-specific tissue antigen; tumor-specific transplantation antigen...
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
TAA Tumor Associated Antigen
TATA Tumor-associated transplantation antigen
MATSA tumor associated surface antigen
T-antigen Tumor antigen
AR Acute Rejection
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • tumor associated antigen
    ¾Ï °ü·Ã Ç׿ø
    ÀϺÎÀÇ Á¤»ó ¼¼Æ÷¿¡¼­¸¸ ¹ß°ßµÇ¾î ÀÖÀ¸³ª ¾Ï ¼¼Æ÷¿¡¼­µµ ¸¹Àº ¹üÀ§¿¡¼­ ¹ßÇöµÈ Ç׿ø, Á¤»ó ¼¼Æ÷¿¡¼­´Â ¹Ì·®ÀÌ Á¸ÀçÇϳª ¾Ï ¼¼Æ÷¿¡¼­´Â ´Ù·®ÀÌ °ËÃâµÇ´Â Ç׿ø, ±×·¯³ª °áÄÚ ¾Ï ƯÀÌÀûÀ̶ó°í ÇÒ ¼ö ¾ø´Â ¼ºÁúÀÇ Ç׿ø.
  • acute rejection vasculitis
    ±Þ¼º °ÅºÎ Ç÷°ü¿°
    ÀÌ½Ä ÈÄ ¸î °³¿ù ³»¿¡ ³ªÅ¸³ª°Å³ª ¸é¿ª¾ïÁ¦¿ä¹ýÀ» Áß´ÜÇßÀ» ¶§ ¹ß»ýÇÒ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ È¯ÀÚ´Â ÀÌ½Ä Àå±âÀÇ ±â´ÉÀå¾Ö°¡ ÀÌ½Ä ¼ö¼ú ÈÄ °©Àڱ⠳ªÅ¸³ª¼­ Áö¼Ó¼ºÀ» º¸ÀÌ¸ç °í´ÜÀ§ÀÇ ¸é¿ª¾ïÁ¦¿ä¹ý¿¡ ÀÇÇØ¼­µµ Àß Ä¡À¯µÇÁö ¾Ê´Â´Ù.
  • adeno-associated virus
    ¾Æµ¥³ë °ü·Ã ¹ÙÀÌ·¯½º
  • allogenic rejection
    µ¿Á¾ ÀÌ½Ä °ÅºÎ
    µ¿Á¾ ÀÌ½ÄÆíÀÌ »ýÂøÇÏ´Â ÀÏÀÌ ¾øÀÌ °ÅºÎ´çÇØ¹ö¸®´Â °Í. ÀÌ½ÄÆí°ú °³Ã¼ »çÀÌÀÇ Á¶Á÷ ÀûÇÕ¼º Ç׿øÀÌ ´Ù¸£¸é À̵éÀÇ Ç׿ø¿¡ ´ëÇÑ ¼÷ÁÖÀÇ ¸é¿ª¹ÝÀÀÀÌ ¹æ¾Æ¼è°¡ µÇ¾î ÀÌ½ÄÆíÀÇ ÆÄ±«, Áï ÀÌ½Ä °ÅºÎÀÇ Çö»óÀÌ ¹ß»ýÇÑ´Ù. °ÅºÎÀÇ ÁÖ¿ªÀ» ÇØ³»´Â °ÍÀº ¼¼Æ÷¼º ¸é¿ªÀ̶ó°í ÇÑ´Ù.
  • associated
    µ¿¹ÝÀÇ, ¼ö¹ÝÀÇ, °ø¾×ÀÇ, ¿¬ÇÕÀÇ
  • associated symptom
    °ü·Ã Áõ»ó
  • complete rejection
    ÀüÀûÀÎ °ÅºÎ
  • first set rejection
    ÀÏÂ÷ °ÅºÎ, ÀÏÂ÷ °ÅºÎ ¹ÝÀÀ
    Á¦ 1ȸ°ÀÇ µ¿Á¾ À̽Ŀ¡ ÀϾ´Â °ÅºÎ ¹ÝÀÀÀÇ ¾ç½ÄÀÌ¸ç ºÎÀûÇÕÀÇ Á¤µµ¿¡ µû¶ó 1-3ÁÖ°£ÀÇ Àẹ±â¸¦ °ÅÃÄ ÀÌ½Ä ÆíÀº Å»¶ôÇÑ´Ù. ÀÌ½Ä °ÅºÎ ¹ÝÀÀµµ ºñÀÚ±âÀÇ Ç׿ø¼ºÀ» °¡Áø ¼¼Æ÷¸¦ Á¦°ÅÇϱâ À§ÇÑ ¸é¿ª ¹ÝÀÀÀÌ´Ù.
  • HIV associated periodontal disease
    HIV¿Í °ü·ÃµÈ Ä¡ÁÖ Áúȯ
  • homograft rejection
    µ¿Á¾ ÀÌ½ÄÆí °ÅºÎ ¹ÝÀÀ
    µ¿ÀÏÇÑ Á¾ ³»¿¡¼­ÀÇ À̽Ŀ¡ ´ëÇÑ °ÅºÎ ¹ÝÀÀ.
  • immunologic rejection
    ¸é¿ªÇÐÀû °ÅºÎ
  • lateral cord and associated anterior cornual syndrome
    Ãø»è µ¿Ãø Àü°¢ ÁõÈıº
  • proximal tubular rejection
    ÀÎÁ¢ µµ°ü ºÀ¼â
  • rejection
    °ÅÀý, °ÅºÎ, ±â°¢, °ÅºÎ ¹ÝÀÀ
    ÀÌ½Ä Á¶Á÷¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀ. °úÀ× ¿¹¹Î¼º °ÅºÎ·Î ±âÁ¸ÀÇ Ç×ü¿¡ ÀÇÇÏ¿© ÀÌ½ÄÆí¿¡ ´ëÇÑ Áï½Ã ÀÀ´ä ¹ÝÀÀÀÌ ÀϾ ¼¶À¯¼Ò Ä§Âø, Ç÷¼ÒÆÇ ÀÀÁý, È£Áß±¸ ħÀ±ÀÌ ÀϾ¸ç °á±¹Àº À̽ÄÀÇ ½ÇÆÐ·Î ³¡³­´Ù.
  • self-associated rheumatoid factor complex

    self-care (ÀÚ°¡ Ä¡·á

CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
tumor 1. <oncology> An abnormal mass of tissue that results from excessive cell division that is uncontrolled and progressive, also called a neoplasm. Tumours perform no useful body function. They may be either benign (not cancerous) or malignant.
2. Swelling, one of the cardinal signs of inflammations, morbid enlargement.
Origin: L. Tumere = to swell
(12 May 1997)
tumor marker <investigation, oncology> A substance in the body that usually indicates the presence of cancer.
These markers are usually specific to certain types of cancer and are usually found in the blood or other tissue samples.
Examples are alphafetoprotein (AFP), human chorionic gonadotropin, and lactate dehydrogenase (LDH).
They may be indicators of tumour stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
(18 Jul 2002)
tumor necrosis factor <cytokine> Originally described as a tumour inhibiting factor in the blood of animals exposed to bacterial lipopolysaccharide or Bacille Calmette-Guerin.
Preferentially kills tumour cells in vivo and in vitro, causes necrosis of certain transplanted tumours in mice and inhibits experimental metastases. Human Tumour Necrosis factor alpha is a protein of 157 amino acids and has a wide range of pro inflammatory actions. Usually considered a cytokine.
Synonym: cachectin.
Acronym: TNF
(13 Nov 1997)
hepatitis-associated antigen A term used for the surface antigen of hepatitis B virus before its nature was established.
See: hepatitis B surface antigen.
(05 Mar 2000)
Ir associated antigen Antigens coded for by IR (immune response) genes or antigens coded for by the genome close to the IR genes.
See: Ia antigens.
(18 Nov 1997)
tumour-associated antigen Antigens that are highly correlated with certain tumour cells. They are not usually found, or are found to a lesser extent, on normal cells.
(05 Mar 2000)
lymphocyte function associated antigen A member of the integrin family that is expressed on all leukocytes and binds to ICAM-1 and ICAM-2 on a variety of cells.
(05 Mar 2000)
lymphocyte function-associated antigen-1 A heterodimer molecule widely expressed on cells of haematopoietic origin. Cd11a antigen comprises the alpha chain and the CD18 antigen (antigens, CD18) the beta chain. Lfa-1 is a major receptor of T-cells, B-cells, and granulocytes. It mediates the leukocyte adhesion reactions underlying cytolytic conjugate formation, helper T-cell interactions, and antibody-dependent killing by natural killer cells and granulocytes. Intracellular adhesion molecule-1 (icam-1) has been defined as a ligand for lfa-1.
(12 Dec 1998)
accelerated rejection A transplant rejection manifested in less than three days.
(05 Mar 2000)
acute cellular rejection Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage.
See: primary rejection.
Synonym: acute rejection.
(05 Mar 2000)
acute kidney transplant rejection <radiology> Findings on ultrasound: globular enlargment of the kidney, swelling and hypoechogenicity of the medullary pyramids, indistinct cortico-medullary junction, foci in the renal cortex
(12 Dec 1998)
acute rejection Graft rejection which usually begins within 10 days after a graft has been transplanted into a genetically dissimilar host. Lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages which cause tissue damage.
See: primary rejection.
Synonym: acute rejection.
(05 Mar 2000)
allograft rejection The rejection of tissue transplanted between two genetically different individuals of the same species. Rejection is caused by T lymphocytes responding to the foreign major histocompatibility complex of the graft.
Synonym: homograft.
(05 Mar 2000)
parental rejection Withholding of affection from or denial of attention to one's child.
Child's withholding of affection from its parent.
(05 Mar 2000)
rejection 1. <immunology, surgery> Usually used of grafts. Any process leading to the destruction or detachment of a graft or other specified structure.
2. <psychology> Non-acceptance, negative attitudes, hostility or excessive criticism of the individual which may precipitate feelings of rejection.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • associated
    ¿¬ÇÕÇÑ
  • tumor
    Á¾±â
  • associated
    ¿¬ÇÕÇÑ;Á¶ÇÕÀÇ;ÇÕµ¿ÀÇ
  • tumor
    Á¾Ã¢;ºÎ±â;Á¾±â
  • HY antigen
    H-YÇ׿ø(Y¿°»öü À¯ÀüÀÚ¿¡ ÀÇÁ¸ÇÏ´Â Á¶Á÷ ÀûÇÕ Ç׿ø)
  • Rhesus factor(antigen)
    =RH FACTOR
  • antigen
    Ç׿ø(Ç÷¾×Áß¿¡ antibodyÀÇ Çü¼ºÀ» ÃËÁøÇÏ´Â ¹°Áú)
  • histiocompatibility antigen
    Á¶Á÷ ÀûÇÕ¼º Ç׿ø
  • rejection
    °ÅÀý
  • rejection
    ¹èÁ¦;Æó±â;°ÅÀý;°¢ÇÏ;ºÎ°á;±¸Åä;Æó±â¹°;°ÅºÎ(°ÅÀý)¹ÝÀÀ
  • rejection front
    °ÅºÎ Àü¼±(À̽º¶ó¿¤°ú ±³¼·.È­ÆòÀ» °ÅºÎÇÏ´Â ¾Æ¶øÁ¦±¹(Á¶Á÷)ÀÇ Àü¼±)
  • rejection slip
    (ÃâÆÇ»ç°¡ äÅà ¾Ê±â·Î ÇÑ ¿ø°í¿¡ ºÙ¿© º¸³»´Â)°ÅÀý ÂÊÁö;°ÅÀýÇ¥
  • rejection stmptom
    °ÅºÎ ¹ÝÀÀ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á